title: [L-type fatty acid binding protein (L-FABP) and kidney disease].
abstract: Liver-type fatty acid binding protein (L-FABP) is expressed in the cytoplasm of human renal proximal tubules. Renal L-FABP expression is up-regulated and urinary excretion of renal L-FABP is increased by various stressors, such as urinary protein, hyperglycemia, tubular ischemia, toxins, and salt-sensitive hypertension, which lead to the progression of kidney disease. Urinary L-FABP levels accurately reflect the degree of tubulointerstitial damage and are strongly correlated with the prognosis of chronic kidney disease (CKD) patients in clinical studies. In patients with type I or type II diabetes, urinary L-FABP levels were reported to be significantly higher in patients with normal levels of urinary albumin than in those with microalbuminuria. Urinary L-FABP may be useful for the early detection of diabetic nephropathy. Furthermore, in a longitudinal study, a higher level of urinary L-FABP was found to be a risk factor for the progression of diabetic nephropathy. With respect to acute kidney disease (AKI), urinary L-FABP facilitates the early detection of AKI before an increase in serum creatinine. Therefore, urinary L-FABP was approved as a new tubular biomarker by the Ministry of Health, Labour and Welfare of Japan.
authors.forename: Atsuko
authors.initials: A
authors.lastname: Kamijo-Ikemori
authors.forename: Takeshi
authors.initials: T
authors.lastname: Sugaya
authors.forename: Kenjiro
authors.initials: K
authors.lastname: Kimura
mesh_terms: D015415:Biomarkers / Q000097:blood / Q000652:urine; D050556:Fatty Acid-Binding Proteins / Q000097:blood* / Q000652:urine*; D006801:Humans; D007564:Japan; D007674:Kidney Diseases / Q000097:blood / Q000175:diagnosis* / Q000628:therapy / Q000652:urine; D011485:Protein Binding
chemical_list: D015415:Biomarkers; D050556:Fatty Acid-Binding Proteins